TG Therapeutics UTX-TGR-205
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma OPEN COHORTS: MANTLE CELL, FOLICULAR LYMPHOMA, Marginal Zone
A phase I/II study of BTCT4465A in patients who do not achieve CR to 1L therapy for DLBCL and as 1L therapy for patients unfit to receive full-dose anthracycline-based chemotherapy Regulatory Packet sent to Sponsor.
TG Therapeutics TG-1501-101
A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma
Aptose APTO-CG-806- 01
A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin’s Lymphomas
AstraZeneca/ Acerta D8227C00001 (ACE-LY-312)
AstraZeneca/ Acerta D8227C00001 (ACE-LY-312) A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.
Phase II study of pembrolizumab in combination with R-CHOP for patients with untreated, high-risk, non-germinal center-derived DLBCL
Phase II study of pembrolizumab for PD-L1 gene-altered, relapsed/refractory DLBCL